Radezolid - Melinta Therapeutics

Drug Profile

Radezolid - Melinta Therapeutics

Alternative Names: RX-01667; Rx-01_667; RX-103; RX-1741

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rib-X Pharmaceuticals
  • Developer Melinta Therapeutics; Unknown
  • Class Antibacterials; Oxazolidinones; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne vulgaris; Community-acquired pneumonia; Gram-positive infections; Skin and soft tissue infections

Most Recent Events

  • 13 Nov 2017 Phase-II clinical trials in Acne vulgaris (Topical)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Gram-positive-infections(In volunteers) in USA (IV, Infusion)
  • 10 Oct 2017 Melinta Therapeutics completes enrolment in its phase I trial for Acne vulgaris (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top